ClinicalTrials.gg
RecruitingNCT07359482ESPRITUpdated Jun 9, 2026

sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19

A Phase 3 interventional study of Fluvoxamine and Placebo in Post-COVID, POST-Covid 19 and Post-COVID Conditions, sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands — 6 open to participants now, 6 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Netherlands.

Started
2026
with 2 others
Phase 3
3 of 15
3 open now
Registered
15th of 15
by date
Lead sponsor
3 of 15
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Among the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, this one is one of 3 that started in 2026, is one of 3 in phase 3, and was the 15th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

6 of the 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Post-Acute COVID-19 Syndrome with a site in Netherlands, or all of them as a file.
02

Study summary

Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are common and debilitating symptoms after COVID-19. The pathophysiology of post-COVID is not well understood and there is no established biomedical treatment. Treatment options for post-COVID are thus much needed.

A promising candidate intervention is fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), that may reduce post-COVID symptoms because of its regulatory effect on the (neuro) immune system, the hypothalamic-pituitary-adrenal (HPA) axis and the tryptophan system. The investigators will randomize 160 participants to either fluvoxamine or placebo for 12 weeks.

The investigators will use advanced functional neuroimaging techniques during cognitive challenge (optional substudy) and plasma biomarkers (inflammatory markers, cortisol, serotonin, IDO-2 activity), to facilitate identifying potential mechanistic pathways of post -COVID treatment.

Read the detailed description

In this randomized placebo-controlled trial, the investigators will study the effectiveness of fluvoxamine in reducing fatigue severity (primary outcome), cognitive problems, PEM and POTS after 12 weeks of treatment in 160 post-COVID patients.

Moreover, the investigators will study treatment-emergent changes in plasma biomarkers, including blood-based neuro)inflammatory markers, cortisol, serotonin, aryl hydrocarbon receptor -indoleamine 2,3-dioxygenase-2 (IDO-2) and kynurenine pathway (KP) metabolites for potential mechanistic pathways of post-COVID treatment.

Numerous studies have indicated involvement of brain dysfunction in post COVID, which also relate to the degree of symptom severity (e.g. fatigue / cognitive problems). In an optional neuro-imaging sub-study, the investigators will use functional neuroimaging techniques with and without cognitive challenge to gain a better understanding of the brain functioning and structure in long COVID during fluvoxamine treatment versus placebo.

Objectives:

  • To determine if fluvoxamine treatment (50 mg to 200 mg daily dosing) results in lower levels of fatigue severity than placebo after 12 weeks of treatment (primary).
  • To determine if fluvoxamine treatment results in lower levels of PEM and POTS and a better cognitive functioning and health-related quality of life (HRQL) than placebo.
  • To determine if changes in symptoms, i.e. fatigue severity, PEM, POTS, cognitive symptoms, are related to changes in biomarkers, i.e., (neuro)inflammation markers, cortisol, serotonin and IDO-2 -KP metabolites.
  • To determine if biomarkers, i.e., (neuro)inflammation markers, cortisol, serotonin and IDO-2- KP metabolites, change from baseline to week 12 in participants who received fluvoxamine.

Optional Neuro-imaging sub-study:

-To determine which changes occur on functional brain imaging, brain metabolites and neuroinflammation during cognitive challenge and to determine if this brain response to cognitive challenge changes after fluvoxamine treatment versus placebo.

03

Conditions studied

  • Post-COVID
  • POST-Covid 19
  • Post-COVID Conditions

Keywords

  • post-COVID
  • fluvoxamine
  • fatigue
  • biomarkers
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 to 70 years
  • Severely fatigued (CIS fatigue score ≥ 35) at screening
  • Fatigue started/increased significantly after Covid-19 (self-declared)
  • Fatigue symptoms must be present for at least 3 months following the acute infection.
  • Self-reported confirmation of having a SARS-CoV-2 infection by: Positive SARS-CoV-2 nucleic acid amplification test (NAAT), such as PCR; Positive SARS-CoV-2 rapid diagnostic test, including home-administered tests; COVID-19 diagnosis by a medical specialist (GP or in-hospital), based on the above or other clinical test or assessments. The above information will not be verified in medical records.
  • Command of Dutch or English language to complete questionnaires
  • Able to participate in video calling.
  • Willing and able to provide
  • Allowing the trial team to exchange medical information that is relevant for the participants' safety and trial assessments with their GP and pharmacy.

Exclusion criteria

Exclusion Criteria:

  • Use of medication with interaction with fluvoxamine that cannot be discontinued
  • Hospitalized in the acute phase of Covid-19
  • Psychiatric/somatic disorders that could explain the severity of fatigue
  • Neurodegenerative disorders (i.e. M Parkinson, Multiple sclerosis, M Alzheimer)
  • Suicidality (current or recent) (according to WHO suicide screener)
  • Starting or started with other medication intended to reduce post-covid symptoms during the last 2 months
  • Pregnancy (a positive urine or serum pregnancy test) or unwilling to use standard
  • Brugada- or Long syndrome
  • epilepsy, porphyria, history of severe liver impairment
  • known allergies to fluvoxamine or placebo/
  • known current alcohol or drug use problems.
  • Bleeding disorders and past medical history of bleeding gastric or duodenal ulcers or other significant bleeding disorders
  • claustrophobia (optional MRI substudy)
  • having metal implants (optional MRI substudy)
  • inability to lay still for 45 minutes (optional MRI substudy)
  • Neurotrauma/ large stroke or brain abnormalities interfering with image analyses (optional MRI substudy)
  • Inability to come to the Amsterdam UMC (optional MRI substudy).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Intervention arm

    Fluvoxamine.

    Drug: Fluvoxamine

  • Placebo comparator
    Control arm

    Placebo

    Drug: Placebo

Interventions

  • Subject are randomized in a double-blind manner (1:1 ratio) between fluvoxamine and placebo. During the first week subjects will receive a low dose daily dose of fluvoxamine of 25 mg or placebo. In the second week, subjects will receive a daily dose of 50 mg or placebo. From week 3 onwards, the fluvoxamine or placebo dose is increased by daily 50 mg every 6 days in a blinded manner but will not be further increased if participants are unwilling to accept a dose increase. For doses higher than 100 mg per day, dosing is done twice daily. The dose is increased to a maximum of 200 mg per day (i.e. 100 mg bid). The minimal daily dose is 50 mg.

  • DrugPlacebo

    Subject are randomized in a double-blind manner (1:1 ratio) between fluvoxamine and placebo. During the first week subjects will receive a low dose daily dose of fluvoxamine of 25 mg or placebo. In the second week, subjects will receive a daily dose of 50 mg or placebo. From week 3 onwards, the fluvoxamine or placebo dose is increased by daily 50 mg every 6 days in a blinded manner but will not be further increased if participants are unwilling to accept a dose increase. For doses higher than 100 mg per day, dosing is done twice daily. The dose is increased to a maximum of 200 mg per day (i.e. 100 mg bid). The minimal daily dose is 50 mg.

06

What researchers measure

Primary outcomes

  1. Fatigue severity

    Fatigue scale of the Checklist Individual Strength (CIS-20R). This scale has a minimum score of 8 and a maximum score of 56. High score indicate worse outcome.

    Time frame: week 12

Secondary outcomes

  1. Fatigue severity

    Dutch-Flemish Patient-Reported Outcome Measurement Information System (PROMIS) Fatigue short form 8a. A higher scores indicates worse outcome.

    Time frame: week 4, 8, 12

  2. Cognitive functioning

    Dutch-Flemish Patient-Reported Outcome Measurement Information System (PROMIS) cognitive function 8a. Higher scores indicate better functioning.

    Time frame: week 4, 8, 12

  3. Cognitive functioning

    Concentration score on the Checklist Individual Strength (CIS-20R). This scale has a minimum score of 5 and a maximum score of 35. A higher score indicates worse outcome.

    Time frame: week 4, 8, 12

  4. PEM

    DePaul Symptom Questionnaire (DSQ) Post Exertional Malaise (PEM). Higher scores indicate worse outcome.

    Time frame: week 4, 8, 12

  5. POTS (National Aeronautics and Space Administration (NASA) lean test

    NASA lean test

    Time frame: week 12

  6. POTS

    DePaul Symptom Questionnaire (DSQ) Postural Orthostatic Tachycardia Syndrome (POTS). Higher scores indicate worse outcome.

    Time frame: week 4, 8, 12

  7. Health-related Quality of Life

    Dutch-Flemish Patient-Reported Outcome Measurement Information System (PROMIS) Profile-29. Higher scores indicate better outcome.

    Time frame: week 4, 8, 12

  8. Disability

    Bell disability score. The minimum score is 0. The maximum score is 100. Higher scores indicate better outcome.

    Time frame: week 4, 8, 12

  9. Side effects

    Antidepressant Side Effect Checklist-21 (ASEC-21). Higher scores indicate worse outcome.

    Time frame: week 12

  10. Side effects

    Frequency, Intensity, Burden of Side Effects Rating scale (FIBSER scale). Higher scores indicate worse outcome.

    Time frame: week 12

  11. Brain Perfusion (optional MRI substudy)

    Arterial Spin Labeling

    Time frame: week 12

  12. Brain functioning and connectivity (optional MRI substudy)

    During resting-state and cognitive effort (challenging N-back (3-back vs. 0-back) on functional MRI

    Time frame: week 12

  13. Brain metabolites and neuroinflammation (optional MRI substudy)

    Magnetic Resonance Spectroscopy

    Time frame: week 12

Other outcomes

  1. Biomarkers

    (neuro) inflammation markers, corticoid receptor activity and cortisol, serotonin, IDO-2/ KP metabolites

    Time frame: week 12

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Sharing will be in accordance with Dutch privacy laws and regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2026
First posted
Jan 22, 2026
StartActual
Jun 4, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
May 1, 2028
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07359482
Responsible party
Pythia Nieuwkerk (Principal investigator, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)) — Principal investigator
First posted
Jan 22, 2026
Start date
Jun 4, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Jun 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluvoxamine

Start the discussion